AI-Driven Precision Oncology Startup aiPTO Unveils #1-Ranked DELPHAI Model, Bridging the "Scale Gap" From Virtual Cells to Virtual Tumors
Company press release, single-party claim, pending independent verification (not evidence of model performance). The release states that DELPHAI achieved the #1 ranking on differentially expressed gene recovery in two benchmarking frameworks (Wei et al., Nat Methods 2026, DOI 10.1038/s41592-025-02980-0; Radig et al., Genome Biol 2026, DOI 10.1186/s13059-026-04104-z), describes a 'Fitness Gating' mechanism, and says the company's IPTO organoid platform covers 500+ patients across 40+ CNS tumor subtypes (company figure). No numerical results are given; training on IPTO data is described as in progress. Relates to VC0147.
- Authors / organisation
- aiPTO TechBio (Business Wire press release)
- Venue
- Business Wire
- Date
- 2026-10-08
- Type
- news
- Year
- 2026
- Source
- https://www.businesswire.com/news/home/20261008324150/en/AI-Driven-Precision-Oncology-Startup-aiPTO-Unveils-1-Ranked-DELPHAI-Model-Bridging-the-Scale-Gap-From-Virtual-Cells-to-Virtual-Tumors
- Verification
- Business Wire release URL (date 20261008 in URL; full text read via TMCnet syndicated copy dated 2026-10-08; businesswire.com page itself not retrievable by our tools)
Cited by GlioState topics
Not yet cited in any research topic page.
Entities mentioned
- DELPHAI Models
- Patient-derived GBM organoids Models